Group items tagged

Participatory medicine will owe part of its success to the technologies that have the potential to remove treatment, symptom management, administrative, and communications burdens from individuals and clinicians while maintaining the critical interpersonal interactions between them. Out of the steady stream of new devices, programs, gadgets, and applications, which will make a difference in the health and lives of patients? We hope to build the Journal as a resource for critical reviews of technologies that support and facilitate participatory medicine. We realize it will be no small undertaking to put together a process that will allow for the review of a substantial number of technologies over time, reflecting the experience of different types of users.

Journal of Skin CancerVolume 2011 (2011), Article ID 571734, 6 pagesdoi:10.1155/2011/571734 © 2011 Mary H. Lien and Vernon K. Sondak.

The HHS Agency for Healthcare Research and Quality (AHRQ) has announced plans for spending its $300 million share of the $1.1 billion Congress appropriated for comparative effectiveness research (CER) under the American Recovery and Reinvestment Act of 2009 (ARRA or Recovery Act for short). AHRQ plans to solicit grant applications this fall and award grants and contracts by spring 2010. The $300 million must be encumbered by end of FFY 2010.

PDF, Free full text article... We found that 5% imiquimod cream is aneffective treatment option for superficial and nodularbasal cell carcinomas, giving a clearance rate of89.5% at an average of 39 months of follow up.   Dr Yin Vun, Siller Medical, 9th Floor, SilvertonPlace, 101 Wickham Terrace, Brisbane, Qld 4000, Australia.

ATryn (antithrombin alfa) Treatment for Antithrombin III Deficiency - BLA Submitted for ATryn\nGTC Biotherapeutics Completes BLA Submission For ATryn

Wayne Shorter 4tet / Sanctuary / Philharmonie, Köln 2008 // Danilo Perez-piano, John Patitucci-bass, Brian Blade-drums VIDEO: http://tr.im/DHhO